Becton Dickinson (BDX) Q3 2026 Earnings Report

The call conveyed strong execution across BD's focused med‑tech portfolio: revenue and adjusted EPS beat expectations, growth platforms showed double-digit expansion, productivity and cash flow improved materially, and the company raised EPS guidance. Headwinds are defined and manageable — chiefly Alaris remediation, tariffs, vaccine weakness in China and some margin pressure versus the prior year — and management laid out clear mitigation actions (pricing, productivity, commercial investments, AI for supply chain). Overall the positives materially outweigh the negatives.

BD updated fiscal '26 guidance, saying revenue is now expected toward the high end of its low single‑digit FX‑neutral range (currency now a ~100 bp tailwind at current spot rates) and raising the midpoint of adjusted EPS guidance to a range of $12.62–$12.72; the company still expects adjusted operating margin of about 25% (inclusive of tariffs) and an adjusted effective tax rate of 16–17%. Management cited Q3 results of $5.0B revenue (up 4.4%), adjusted gross margin of 54.3%, adjusted operating margin of 24.9% and adjusted EPS of $3.23 as the basis for the update, noted tariffs trimmed margins by roughly 110 bps, and highlighted YTD free cash flow of $1.7B (up 45%) and $3.1B returned to shareholders ($2.3B repurchases, $0.9B dividends) with net leverage ~2.9x (2.5x target). Looking to FY‑27, management reiterated a low single‑digit revenue starting point with a defined ~200 bp Alaris headwind next year and said it expects only “modest” EPS leverage off that baseline, with pricing, BD Excellence productivity and favorable mix helping to offset headwinds and a longer‑term free cash flow conversion goal of ~90%.